TY - JOUR AU - Utens, C. AU - Dirksen, C. AU - Weijden, T. AU - Joore, M. A. PY - 2015 DA - 2015// TI - How to integrate research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guidelines: a qualitative study among Dutch stakeholders JO - Health Policy VL - 120 UR - https://doi.org/10.1016/j.healthpol.2015.10.005 DO - 10.1016/j.healthpol.2015.10.005 ID - Utens2015 ER - TY - JOUR AU - Overbeeke, E. AU - Whichello, C. AU - Janssens, R. AU - Veldwijk, J. AU - Cleemput, I. AU - Simoens, S. PY - 2019 DA - 2019// TI - Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review JO - Drug Discov Today VL - 24 UR - https://doi.org/10.1016/j.drudis.2018.09.015 DO - 10.1016/j.drudis.2018.09.015 ID - Overbeeke2019 ER - TY - JOUR AU - Parsons, S. AU - Starling, B. AU - Mullan-Jensen, C. AU - Tham, S. G. AU - Warner, K. AU - Wever, K. PY - 2016 DA - 2016// TI - What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? a qualitative interview study JO - BMJ Open VL - 6 UR - https://doi.org/10.1136/bmjopen-2015-008928 DO - 10.1136/bmjopen-2015-008928 ID - Parsons2016 ER - TY - JOUR AU - Lowe, M. M. AU - Blaser, D. A. AU - Cone, L. AU - Arcona, S. AU - Ko, J. AU - Sasane, R. PY - 2016 DA - 2016// TI - Increasing patient involvement in drug development JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.04.009 DO - 10.1016/j.jval.2016.04.009 ID - Lowe2016 ER - TY - STD TI - Crocker JC, Boylan AM, Bostock J, Locock L. Is it worth it? Patient and public views on the impact of their involvement in health research and its assessment: a UK-based qualitative interview study. Health Expect. 2017;20(3):519–28. ID - ref5 ER - TY - BOOK AU - Christiaens, W. AU - Kohn, L. AU - Léonard, C. AU - Denis, A. AU - Daue, F. AU - Cleemput, I. PY - 2012 DA - 2012// TI - Models for citizen and patient involvement in health care policy - Part I: exploration of their feasibility and acceptability. Health Services Research (HSR) PB - Belgian Health Care Knowledge Centre (KCE) CY - Brussels ID - Christiaens2012 ER - TY - STD TI - Abelson J, Wagner F, DeJean D, Boesveld S, Gauvin FP, Bean S, et al. Public and patient involvement in health technology assessment: A framework for action. Int J Technol Assess Health Care. 2016;32(4):256–64. ID - ref7 ER - TY - JOUR AU - Bilvick Tai, B. W. AU - Bae, Y. H. AU - Le, Q. A. PY - 2016 DA - 2016// TI - A systematic review of health economic evaluation studies using the patient’s perspective JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.05.010 DO - 10.1016/j.jval.2016.05.010 ID - Bilvick Tai2016 ER - TY - JOUR AU - Menon, D. AU - Stafinski, T. PY - 2011 DA - 2011// TI - Role of patient and public participation in health technology assessment and coverage decisions JO - Expert Rev Pharmacoecon Outcomes Res VL - 11 UR - https://doi.org/10.1586/erp.10.82 DO - 10.1586/erp.10.82 ID - Menon2011 ER - TY - JOUR AU - Tseng, E. K. AU - Hicks, L. K. PY - 2016 DA - 2016// TI - Value based care and patient-centered care: divergent or complementary? JO - Curr Hematol Malig Rep VL - 11 UR - https://doi.org/10.1007/s11899-016-0333-2 DO - 10.1007/s11899-016-0333-2 ID - Tseng2016 ER - TY - JOUR AU - Schunemann, H. J. AU - Fretheim, A. AU - Oxman, A. D. PY - 2006 DA - 2006// TI - Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement JO - Health Res Policy Syst VL - 4 UR - https://doi.org/10.1186/1478-4505-4-22 DO - 10.1186/1478-4505-4-22 ID - Schunemann2006 ER - TY - STD TI - The european parliament and the council of the european union. Directive 2001/83/ec of the european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use. 2001. ID - ref12 ER - TY - STD TI - The council of the european communities. Council directive 93/42/eec of 14 june 1993 concerning medical devices. 1993. ID - ref13 ER - TY - STD TI - US Food and Drug Administration. Classification of Products as Drugs and Devices & Additional Product Classification Issues: Guidance for Industry and FDA Staff. New Hampshire Avenue, Silver Spring, MD 20993. 2017. Retrieved from https://www.fda.gov/media/80384/download. UR - https://www.fda.gov/media/80384/download ID - ref14 ER - TY - JOUR AU - Mühlbacher, A. C. AU - Juhnke, C. AU - Beyer, A. R. AU - Garner, S. PY - 2016 DA - 2016// TI - Patient-focused benefit-risk analysis to inform regulatory decisions: the European union perspective JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.04.006 DO - 10.1016/j.jval.2016.04.006 ID - Mühlbacher2016 ER - TY - JOUR AU - Johnson, F. R. AU - Zhou, M. PY - 2016 DA - 2016// TI - Patient preferences in regulatory benefit-risk assessments: a US perspective JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.04.008 DO - 10.1016/j.jval.2016.04.008 ID - Johnson2016 ER - TY - JOUR AU - Joy, S. M. AU - Little, E. AU - Maruthur, N. M. AU - Purnell, T. S. AU - Bridges, J. F. PY - 2013 DA - 2013// TI - Patient preferences for the treatment of type 2 diabetes: a scoping review JO - Pharmacoeconomics VL - 31 UR - https://doi.org/10.1007/s40273-013-0089-7 DO - 10.1007/s40273-013-0089-7 ID - Joy2013 ER - TY - JOUR AU - Weernink, M. G. M. AU - Janus, S. I. M. AU - Til, J. A. AU - Raisch, D. W. AU - Manen, J. G. AU - Ijzerman, M. J. PY - 2014 DA - 2014// TI - A systematic review to identify the use of preference elicitation methods in healthcare decision making JO - Pharm Med VL - 28 UR - https://doi.org/10.1007/s40290-014-0059-1 DO - 10.1007/s40290-014-0059-1 ID - Weernink2014 ER - TY - STD TI - Medical Device Innovation Consortium (MDIC). Patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology: Medical Device Innovation Consortium; 2015. Available from: http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Proof5_Web.pdf. UR - http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Proof5_Web.pdf ID - ref19 ER - TY - JOUR AU - Dirksen, C. D. AU - Utens, C. M. AU - Joore, M. A. AU - Barneveld, T. A. AU - Boer, B. AU - Dreesens, D. H. PY - 2013 DA - 2013// TI - Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study JO - Implement Sci VL - 8 UR - https://doi.org/10.1186/1748-5908-8-64 DO - 10.1186/1748-5908-8-64 ID - Dirksen2013 ER - TY - STD TI - Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324–31. https://doi.org/10.1016/j.drudis.2019.05.001. ID - ref21 ER - TY - STD TI - About PREFER: Uppsala University, Sweden; 2016 [updated 2016-12-14 13:30:48+0100. Available from: http://www.imi-prefer.eu/about/. UR - http://www.imi-prefer.eu/about/ ID - ref22 ER - TY - STD TI - de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project. Patient. 2017;10(3):263-6. ID - ref23 ER - TY - STD TI - Selig WKD. Key considerations for developing & integrating patient perspectives in drug development: examination of the duchenne case study: Biotechnology Innovation Organization and Parent Project Muscular Dystrophy; 2016. Available from: https://www.bio.org/sites/default/files/BIO_PPMD_Paper_2016.pdf. UR - https://www.bio.org/sites/default/files/BIO_PPMD_Paper_2016.pdf ID - ref24 ER - TY - JOUR AU - Til, J. A. AU - Ijzerman, M. J. PY - 2014 DA - 2014// TI - Why should regulators consider using patient preferences in benefit-risk assessment? JO - PharmacoEconomics VL - 32 UR - https://doi.org/10.1007/s40273-013-0118-6 DO - 10.1007/s40273-013-0118-6 ID - Til2014 ER - TY - JOUR AU - Bridges, J. F. P. AU - Paly, V. F. AU - Barker, E. AU - Kervitsky, D. PY - 2014 DA - 2014// TI - Identifying the benefits and risks of emerging treatments for idiopathic pulmonary fibrosis: a qualitative study JO - Patient VL - 8 UR - https://doi.org/10.1007/s40271-014-0081-0 DO - 10.1007/s40271-014-0081-0 ID - Bridges2014 ER - TY - BOOK AU - Marsh, K. PY - 2016 DA - 2016// TI - Incorporating Patient Preferences into Product Development and Value Communication: Why, When and How? The Evidence Forum: A Discourse on Value ID - Marsh2016 ER - TY - JOUR AU - Stewart, K. D. AU - Johnston, J. A. AU - Matza, L. S. AU - Curtis, S. E. AU - Havel, H. A. AU - Sweetana, S. A. PY - 2016 DA - 2016// TI - Preference for pharmaceutical formulation and treatment process attributes JO - Patient Prefer Adherence VL - 10 UR - https://doi.org/10.2147/PPA.S101821 DO - 10.2147/PPA.S101821 ID - Stewart2016 ER - TY - JOUR AU - Mühlbacher, A. AU - Bethge, S. PY - 2016 DA - 2016// TI - What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences JO - Eur J Health Econ VL - 17 UR - https://doi.org/10.1007/s10198-015-0750-5 DO - 10.1007/s10198-015-0750-5 ID - Mühlbacher2016 ER - TY - JOUR AU - Danner, M. AU - Hummel, J. M. AU - Volz, F. AU - Manen, J. G. AU - Wiegard, B. AU - Dintsios, C. M. PY - 2011 DA - 2011// TI - Integrating patients' views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences JO - Int J Technol Assess Health Care VL - 27 UR - https://doi.org/10.1017/S0266462311000523 DO - 10.1017/S0266462311000523 ID - Danner2011 ER - TY - STD TI - Choice-based Conjoint Analysis – pilot project to identify, weight, and prioritize multiple attributes in the indication “hepatitis C”. Institute for Quality and Efficiency in Health Care (IQWiG); 2014. Report No.: GA10–03. ID - ref31 ER - TY - JOUR AU - Evers, P. AU - Greene, L. AU - Ricciardi, M. PY - 2016 DA - 2016// TI - The importance of early access to medicines for patients suffering from rare diseases JO - Regul Rapporteur VL - 13 ID - Evers2016 ER - TY - STD TI - Chow RD, Wankhedkar KP, Mete M. Patients' preferences for selection of endpoints in cardiovascular clinical trials. Journal of community hospital internal medicine perspectives. 2014;4(1):10.3402/jchimp.v4.22643. ID - ref33 ER - TY - JOUR AU - Smith, M. Y. AU - Hammad, T. A. AU - Metcalf, M. AU - Levitan, B. AU - Noel, R. AU - Wolka, A. M. PY - 2016 DA - 2016// TI - Patient engagement at a tipping point—the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the DIA conference, “patient engagement in benefit risk assessment throughout the life cycle of medical products” JO - Ther Innov Regul Sci VL - 50 ID - Smith2016 ER - TY - JOUR AU - Stamuli, E. AU - Torgerson, D. AU - Northgraves, M. AU - Ronaldson, S. AU - Cherry, L. PY - 2017 DA - 2017// TI - Identifying the primary outcome for a randomised controlled trial in rheumatoid arthritis: the role of a discrete choice experiment JO - J Foot Ankle Res VL - 10 UR - https://doi.org/10.1186/s13047-017-0240-3 DO - 10.1186/s13047-017-0240-3 ID - Stamuli2017 ER - TY - JOUR AU - Chaudhuri, S. E. AU - Ho, M. P. AU - Irony, T. AU - Sheldon, M. AU - Lo, A. W. PY - 2018 DA - 2018// TI - Patient-centered clinical trials JO - Drug Discov Today VL - 23 UR - https://doi.org/10.1016/j.drudis.2017.09.016 DO - 10.1016/j.drudis.2017.09.016 ID - Chaudhuri2018 ER - TY - JOUR AU - Ho, M. AU - Saha, A. AU - McCleary, K. K. AU - Levitan, B. AU - Christopher, S. AU - Zandlo, K. PY - 2016 DA - 2016// TI - A Framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.02.019 DO - 10.1016/j.jval.2016.02.019 ID - Ho2016 ER - TY - STD TI - Egbrink MO, Ijzerman M. The value of quantitative patient preferences in regulatory benefit-risk assessment. J Mark Access Health Policy. 2014;2:22761. ID - ref38 ER - TY - JOUR AU - Smith, M. Y. AU - Benattia, I. PY - 2016 DA - 2016// TI - The Patient’s voice in pharmacovigilance: pragmatic approaches to building a patient-centric drug safety organization JO - Drug Saf VL - 39 UR - https://doi.org/10.1007/s40264-016-0426-9 DO - 10.1007/s40264-016-0426-9 ID - Smith2016 ER - TY - JOUR AU - Marsh, K. AU - Caro, J. J. AU - Zaiser, E. AU - Heywood, J. AU - Hamed, A. PY - 2018 DA - 2018// TI - Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences JO - Int J Technol Assess Health Care VL - 34 UR - https://doi.org/10.1017/S0266462317001118 DO - 10.1017/S0266462317001118 ID - Marsh2018 ER - TY - STD TI - Hollin IL, Peay HL, Apkon SD, Bridges JFP. Patient-centered benefit-risk assessment in duchenne muscular dystrophy. Muscle & nerve. 2017;55(5):626–34. ID - ref41 ER - TY - JOUR AU - Postmus, D. AU - Mavris, M. AU - Hillege, H. L. AU - Salmonson, T. AU - Ryll, B. AU - Plate, A. PY - 2016 DA - 2016// TI - Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators JO - Clin Pharmacol Ther VL - 99 UR - https://doi.org/10.1002/cpt.332 DO - 10.1002/cpt.332 ID - Postmus2016 ER - TY - STD TI - Hauber AB, Fairchild AO, Reed Johnson F. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11(4):319–29. ID - ref43 ER - TY - JOUR AU - Mühlbacher, A. C. AU - Kaczynski, A. PY - 2016 DA - 2016// TI - Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA JO - Appl Health Econ Health Policy VL - 14 UR - https://doi.org/10.1007/s40258-015-0203-4 DO - 10.1007/s40258-015-0203-4 ID - Mühlbacher2016 ER - TY - STD TI - Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, et al. Incorporating patient-preference evidence into regulatory decision making. Surgical endoscopy. 2015;29(10):2984–93. ID - ref45 ER - TY - STD TI - The patient’s voice in the evaluation of medicines. European Medicines Agency, Stakeholders and Communication Division; 2013. Report No.: EMA/607864/2013. ID - ref46 ER - TY - JOUR AU - Mühlbacher, A. C. AU - Bridges, J. F. AU - Bethge, S. AU - Dintsios, C. M. AU - Schwalm, A. AU - Gerber-Grote, A. PY - 2017 DA - 2017// TI - Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment JO - Eur J Health Econ VL - 18 UR - https://doi.org/10.1007/s10198-016-0763-8 DO - 10.1007/s10198-016-0763-8 ID - Mühlbacher2017 ER - TY - BOOK AU - Hughes, D. AU - Waddingham, E. A. J. AU - Mt-Isa, S. AU - Goginsky, A. AU - Chan, E. AU - Downey, G. PY - 2013 DA - 2013// TI - Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines ID - Hughes2013 ER - TY - JOUR AU - Peay, H. L. AU - Hollin, I. AU - Fischer, R. AU - Bridges, J. F. PY - 2014 DA - 2014// TI - A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy JO - Clin Ther VL - 36 UR - https://doi.org/10.1016/j.clinthera.2014.04.011 DO - 10.1016/j.clinthera.2014.04.011 ID - Peay2014 ER - TY - JOUR AU - Hummel, M. J. M. AU - Volz, F. AU - Manen, J. G. AU - Danner, M. AU - Dintsios, C. M. AU - Ijzerman, M. J. PY - 2012 DA - 2012// TI - Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment JO - Patient VL - 5 UR - https://doi.org/10.1007/BF03262495 DO - 10.1007/BF03262495 ID - Hummel2012 ER - TY - JOUR AU - Morel, T. AU - Ayme, S. AU - Cassiman, D. AU - Simoens, S. AU - Morgan, M. AU - Vandebroek, M. PY - 2016 DA - 2016// TI - Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0444-9 DO - 10.1186/s13023-016-0444-9 ID - Morel2016 ER - TY - STD TI - Muhlbacher AC. Patient-centric HTA: different strokes for different folks. Expert review of pharmacoeconomics & outcomes research. 2015;15(4):591–7. ID - ref52 ER - TY - JOUR AU - Craig, B. M. AU - Lancsar, E. AU - Muhlbacher, A. C. AU - Brown, D. S. AU - Ostermann, J. PY - 2017 DA - 2017// TI - Health preference research: an overview JO - Patient VL - 10 UR - https://doi.org/10.1007/s40271-017-0253-9 DO - 10.1007/s40271-017-0253-9 ID - Craig2017 ER - TY - JOUR AU - Mott, D. J. AU - Najafzadeh, M. PY - 2016 DA - 2016// TI - Whose preferences should be elicited for use in health-care decision-making? a case study using anticoagulant therapy JO - Expert Rev Pharmacoecon Outcomes Res VL - 16 UR - https://doi.org/10.1586/14737167.2016.1115722 DO - 10.1586/14737167.2016.1115722 ID - Mott2016 ER - TY - JOUR AU - Avila, M. AU - Becerra, V. AU - Guedea, F. AU - Suarez, J. F. AU - Fernandez, P. AU - Macias, V. PY - 2015 DA - 2015// TI - Estimating preferences for treatments in patients with localized prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 91 UR - https://doi.org/10.1016/j.ijrobp.2014.09.044 DO - 10.1016/j.ijrobp.2014.09.044 ID - Avila2015 ER - TY - STD TI - Gutknecht M, Schaarschmidt ML, Herrlein O, Augustin M. A systematic review on methods used to evaluate patient preferences in psoriasis treatments. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016;30(9):1454–64. ID - ref56 ER - TY - JOUR AU - Martin-Fernandez, J. AU - Polentinos-Castro, E. AU - Cura-Gonzalez, M. I. AU - Ariza-Cardiel, G. AU - Abraira, V. AU - Gil-LaCruz, A. I. PY - 2014 DA - 2014// TI - Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences JO - BMC Health Serv Res VL - 14 UR - https://doi.org/10.1186/1472-6963-14-287 DO - 10.1186/1472-6963-14-287 ID - Martin-Fernandez2014 ER - TY - JOUR AU - Marsh, K. AU - Caro, J. J. AU - Hamed, A. AU - Zaiser, E. PY - 2017 DA - 2017// TI - Amplifying each patient’s voice: a systematic review of multi-criteria decision analyses involving patients JO - Appl Health Econ Health Policy VL - 15 UR - https://doi.org/10.1007/s40258-016-0299-1 DO - 10.1007/s40258-016-0299-1 ID - Marsh2017 ER - TY - JOUR AU - Mott, D. J. PY - 2018 DA - 2018// TI - Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? JO - Patient VL - 11 UR - https://doi.org/10.1007/s40271-018-0305-9 DO - 10.1007/s40271-018-0305-9 ID - Mott2018 ER - TY - JOUR AU - Brooker, A. S. AU - Carcone, S. AU - Witteman, W. AU - Krahn, M. PY - 2013 DA - 2013// TI - Quantitative patient preference evidence for health technology assessment: a case study JO - Int J Technol Assess Health Care VL - 29 UR - https://doi.org/10.1017/S0266462313000329 DO - 10.1017/S0266462313000329 ID - Brooker2013 ER - TY - JOUR AU - Roy, A. N. AU - Madhavan, S. S. AU - Lloyd, A. PY - 2015 DA - 2015// TI - A discrete choice experiment to elicit patient willingness to pay for attributes of treatment-induced symptom relief in comorbid. Insomnia JO - Manag Care VL - 24 ID - Roy2015 ER - TY - JOUR AU - Dirksen, C. D. PY - 2014 DA - 2014// TI - The use of research evidence on patient preferences in health care decision-making: issues, controversies and moving forward JO - Expert Rev Pharmacoecon Outcomes Res VL - 14 UR - https://doi.org/10.1586/14737167.2014.948852 DO - 10.1586/14737167.2014.948852 ID - Dirksen2014 ER - TY - JOUR AU - Mol, P. G. AU - Arnardottir, A. H. AU - Straus, S. M. AU - Graeff, P. A. AU - Haaijer-Ruskamp, F. M. AU - Quik, E. H. PY - 2015 DA - 2015// TI - Understanding drug preferences, different perspectives JO - Br J Clin Pharmacol VL - 79 UR - https://doi.org/10.1111/bcp.12566 DO - 10.1111/bcp.12566 ID - Mol2015 ER - TY - STD TI - Muhlbacher AC, Johnson FR. Giving Patients a Meaningful Voice in European Health Technology Assessments: The Role of Health Preference Research. Patient. 2017;10(4):527–30. ID - ref64 ER - TY - JOUR AU - Kievit, W. AU - Tummers, M. AU - Hoorn, R. AU - Booth, A. AU - Mozygemba, K. AU - Refolo, P. PY - 2017 DA - 2017// TI - Taking patient heterogeneity and preferences into account in health technology assessments JO - Int J Technol Assess Health Care VL - 33 UR - https://doi.org/10.1017/S0266462317000885 DO - 10.1017/S0266462317000885 ID - Kievit2017 ER - TY - JOUR AU - Irony, T. AU - Ho, M. AU - Christopher, S. AU - Levitan, B. PY - 2016 DA - 2016// TI - Incorporating patient preferences into medical device benefit-risk assessments JO - Stat Biopharmaceutical Res VL - 8 UR - https://doi.org/10.1080/19466315.2015.1135820 DO - 10.1080/19466315.2015.1135820 ID - Irony2016 ER - TY - JOUR AU - Eichler, H. G. AU - Bloechl-Daum, B. AU - Brasseur, D. AU - Breckenridge, A. AU - Leufkens, H. AU - Raine, J. PY - 2013 DA - 2013// TI - The risks of risk aversion in drug regulation JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd4129 DO - 10.1038/nrd4129 ID - Eichler2013 ER - TY - JOUR AU - Janssen, I. M. AU - Scheibler, F. AU - Gerhardus, A. PY - 2016 DA - 2016// TI - Importance of hemodialysis-related outcomes: comparison of ratings by a self-help group, clinicians, and health technology assessment authors with those by a large reference group of patients JO - Patient Prefer Adherence VL - 10 UR - https://doi.org/10.2147/PPA.S122319 DO - 10.2147/PPA.S122319 ID - Janssen2016 ER - TY - JOUR AU - Collison, K. A. AU - Patel, P. AU - Preece, A. F. AU - Stanford, R. H. AU - Sharma, R. K. AU - Feldman, G. PY - 2018 DA - 2018// TI - A randomized clinical trial comparing the ELLIPTA and HandiHaler dry powder inhalers in patients with COPD: inhaler-specific attributes and overall patient preference JO - COPD: J Chron Obstruct Pulmon Dis VL - 15 UR - https://doi.org/10.1080/15412555.2017.1400000 DO - 10.1080/15412555.2017.1400000 ID - Collison2018 ER - TY - BOOK AU - Hockley, K. AU - Ashby, D. AU - Das, S. AU - Hallgreen, C. AU - Mt-Isa, S. AU - Waddingham, E. PY - 2013 DA - 2013// TI - Patient and Public Involvement Report: Recommendations for Patient and Public Involvement in the assessment of benefit and risk of medicines ID - Hockley2013 ER - TY - JOUR AU - Eichler, H. G. AU - Abadie, E. AU - Baker, M. AU - Rasi, G. PY - 2012 DA - 2012// TI - Fifty years after thalidomide; what role for drug regulators? JO - Br J Clin Pharmacol VL - 74 UR - https://doi.org/10.1111/j.1365-2125.2012.04255.x DO - 10.1111/j.1365-2125.2012.04255.x ID - Eichler2012 ER - TY - JOUR AU - Johnson, F. R. AU - Beusterien, K. AU - Ozdemir, S. AU - Wilson, L. PY - 2017 DA - 2017// TI - Giving patients a meaningful voice in United States regulatory decision making: the role for health preference research JO - Patient VL - 10 UR - https://doi.org/10.1007/s40271-017-0250-z DO - 10.1007/s40271-017-0250-z ID - Johnson2017 ER - TY - STD TI - Patient-Perspective Value Framework (PPVF): Draft Methodology. Avalere and Milken Institute, FasterCures; 2016. ID - ref73 ER - TY - STD TI - Analytic Hierarchy Process (AHP) – pilot project to elicit patient preferences in the indication “depression”. Institute for Quality and Efficiency in Health Care (IQWiG); 2013. ID - ref74 ER - TY - STD TI - Janssen EM, Marshall DA, Hauber AB, Bridges JFP. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert review of pharmacoeconomics & outcomes research. 2017;17(6):531–42. ID - ref75 ER - TY - JOUR AU - Tervonen, T. AU - Gelhorn, H. AU - Sri Bhashyam, S. AU - Poon, J. L. AU - Gries, K. S. AU - Rentz, A. PY - 2017 DA - 2017// TI - MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment JO - Pharmacoepidemiol Drug Saf VL - 26 UR - https://doi.org/10.1002/pds.4255 DO - 10.1002/pds.4255 ID - Tervonen2017 ER - TY - JOUR AU - Janssen, E. M. AU - Longo, D. R. AU - Bardsley, J. K. AU - Bridges, J. F. PY - 2017 DA - 2017// TI - Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment JO - Patient Prefer Adherence VL - 11 UR - https://doi.org/10.2147/PPA.S139471 DO - 10.2147/PPA.S139471 ID - Janssen2017 ER - TY - JOUR AU - Arx, L. B. AU - Johnson, F. R. AU - Morkbak, M. R. AU - Kjaer, T. PY - 2017 DA - 2017// TI - Be careful what you ask for: effects of benefit descriptions on diabetes Patients' benefit-risk tradeoff preferences JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2016.11.023 DO - 10.1016/j.jval.2016.11.023 ID - Arx2017 ER - TY - STD TI - Wolka AM, Fairchild AO, Reed SD, Anglin G, Johnson FR, Siegel M, et al. Effective partnering in conducting benefit-risk patient preference studies: perspectives from a patient advocacy organization, a pharmaceutical company, and academic stated-preference researchers. Ther Innov Regul Sci. 2017. ID - ref79 ER - TY - STD TI - Wolka AM, Fairchild AO, Reed SD, Anglin G, Johnson FR, Siegel M, et al. Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers. Therapeutic innovation & regulatory science. 2018;52(4):507–13. ID - ref80 ER - TY - STD TI - Patient involvement in the HTA decision-making process. Innovative Medicines Initiative, European Patients’ Academy on Therapeutic Innovation (EUPATI); 2016. ID - ref81 ER - TY - STD TI - Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(4):836–42. ID - ref82 ER -